NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab

Alfredomaria Lurati, Luca Bertani, Mariagrazia Marrazza, Katia Angela Re, Daniela Bompane, Magda ScarpelliniRheumatology Unit, Fornaroli Hospital, Magenta, ItalyPurpose: The relationship between antiCD20 therapy with rituximab and the lymphocytes phenotype in patients with rheumatoid arthritis was i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Re KA, Marrazza M, Bertani L, Lurati A, Scarpellini M, Bompane D
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/c6faa4f926904747943482ce1ce7ba1c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c6faa4f926904747943482ce1ce7ba1c
record_format	dspace
spelling	oai:doaj.org-article:c6faa4f926904747943482ce1ce7ba1c2021-12-02T03:15:41ZNK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab1177-54751177-5491https://doaj.org/article/c6faa4f926904747943482ce1ce7ba1c2012-04-01T00:00:00Zhttp://www.dovepress.com/nk-cell-count-as-predictor-of-clinical-response-in-patients-with-rheum-a9663https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Alfredomaria Lurati, Luca Bertani, Mariagrazia Marrazza, Katia Angela Re, Daniela Bompane, Magda ScarpelliniRheumatology Unit, Fornaroli Hospital, Magenta, ItalyPurpose: The relationship between antiCD20 therapy with rituximab and the lymphocytes phenotype in patients with rheumatoid arthritis was investigated, with an attempt to establish a relationship between commonly used clinical activity indices and variations in leukocyte count, in particular natural killer (NK) lymphocytes.Methods: Patients with seropositive (cyclic citrullinated peptides and rheumatoid factor positive) rheumatoid arthritis (according to the American College of Rheumatology 1987 criteria) refractory to conventional and antitumor necrosis factor-alpha agents who were subsequently treated with rituximab, a chimeric monoclonal antibody directed against CD20, were enrolled between January 2009 and September 2009. All subjects were treated with rituximab standard rheumatologic dose of 1.0 g on days 1 and 15 every 6 months for at least 2 years. A clinical evaluation was performed at baseline and subsequently every 3 months thereafter. At each assessment activated NK (CD56+/CD16+/CD54bright) cell count was collected and disease activity was assessed using Disease Activity Score in 28 Joints and the Simplified Disease Activity Index (SDAI).Results: Thirty-four patients were enrolled (mean age &plusmn; standard deviation: 54.8 &plusmn; 12.8 years). Basal SDAI was 21.75 &plusmn; 5.4 and NK cell count mean value was 157.6 &plusmn; 90. After 24 months, SDAI was 14 &plusmn; 1.2 and NK cell count mean value was 301.7 &plusmn; 21 (P &lt; 0.05). An inverted correlation between SDAI and NK count was observed at 3 months (r = -0.36, P &lt; 0.05), 6 months (r = -0.48, P &lt; 0.45), 9 months (r = -0.47, P &lt; 0.05), 12 months (r = -0.41, P &lt; 0.01), 15 months (r = -0.58, P &lt; 0.05), 18 months (r = -0.53, P &lt; 0.05), 21 months (r = -0.68, P &lt; 0.05), and 24 months (r = -0.61, P &lt; 0.05). A linear regression model between all variables collected and SDAI/Disease Activity Score in 28 Joints at 6 months and 12 months confirmed a significant relationship between SDAI/Disease Activity Score in 28 Joints and NK cell count.Conclusion: The data confirm the clinical efficacy of rituximab and suggests the use of NK cells as a predictor of clinical response in patients with rheumatoid arthritis.Keywords: NK cells, rituximab, predictor, response, rheumatoid arthritisRe KAMarrazza MBertani LLurati AScarpellini MBompane DDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2012, Iss default, Pp 83-87 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Re KA Marrazza M Bertani L Lurati A Scarpellini M Bompane D NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab
description	Alfredomaria Lurati, Luca Bertani, Mariagrazia Marrazza, Katia Angela Re, Daniela Bompane, Magda ScarpelliniRheumatology Unit, Fornaroli Hospital, Magenta, ItalyPurpose: The relationship between antiCD20 therapy with rituximab and the lymphocytes phenotype in patients with rheumatoid arthritis was investigated, with an attempt to establish a relationship between commonly used clinical activity indices and variations in leukocyte count, in particular natural killer (NK) lymphocytes.Methods: Patients with seropositive (cyclic citrullinated peptides and rheumatoid factor positive) rheumatoid arthritis (according to the American College of Rheumatology 1987 criteria) refractory to conventional and antitumor necrosis factor-alpha agents who were subsequently treated with rituximab, a chimeric monoclonal antibody directed against CD20, were enrolled between January 2009 and September 2009. All subjects were treated with rituximab standard rheumatologic dose of 1.0 g on days 1 and 15 every 6 months for at least 2 years. A clinical evaluation was performed at baseline and subsequently every 3 months thereafter. At each assessment activated NK (CD56+/CD16+/CD54bright) cell count was collected and disease activity was assessed using Disease Activity Score in 28 Joints and the Simplified Disease Activity Index (SDAI).Results: Thirty-four patients were enrolled (mean age &plusmn; standard deviation: 54.8 &plusmn; 12.8 years). Basal SDAI was 21.75 &plusmn; 5.4 and NK cell count mean value was 157.6 &plusmn; 90. After 24 months, SDAI was 14 &plusmn; 1.2 and NK cell count mean value was 301.7 &plusmn; 21 (P &lt; 0.05). An inverted correlation between SDAI and NK count was observed at 3 months (r = -0.36, P &lt; 0.05), 6 months (r = -0.48, P &lt; 0.45), 9 months (r = -0.47, P &lt; 0.05), 12 months (r = -0.41, P &lt; 0.01), 15 months (r = -0.58, P &lt; 0.05), 18 months (r = -0.53, P &lt; 0.05), 21 months (r = -0.68, P &lt; 0.05), and 24 months (r = -0.61, P &lt; 0.05). A linear regression model between all variables collected and SDAI/Disease Activity Score in 28 Joints at 6 months and 12 months confirmed a significant relationship between SDAI/Disease Activity Score in 28 Joints and NK cell count.Conclusion: The data confirm the clinical efficacy of rituximab and suggests the use of NK cells as a predictor of clinical response in patients with rheumatoid arthritis.Keywords: NK cells, rituximab, predictor, response, rheumatoid arthritis
format	article
author	Re KA Marrazza M Bertani L Lurati A Scarpellini M Bompane D
author_facet	Re KA Marrazza M Bertani L Lurati A Scarpellini M Bompane D
author_sort	Re KA
title	NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab
title_short	NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab
title_full	NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab
title_fullStr	NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab
title_full_unstemmed	NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab
title_sort	nk cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/c6faa4f926904747943482ce1ce7ba1c
work_keys_str_mv	AT reka nkcellcountaspredictorofclinicalresponseinpatientswithrheumatoidarthritistreatedwithrituximab AT marrazzam nkcellcountaspredictorofclinicalresponseinpatientswithrheumatoidarthritistreatedwithrituximab AT bertanil nkcellcountaspredictorofclinicalresponseinpatientswithrheumatoidarthritistreatedwithrituximab AT luratia nkcellcountaspredictorofclinicalresponseinpatientswithrheumatoidarthritistreatedwithrituximab AT scarpellinim nkcellcountaspredictorofclinicalresponseinpatientswithrheumatoidarthritistreatedwithrituximab AT bompaned nkcellcountaspredictorofclinicalresponseinpatientswithrheumatoidarthritistreatedwithrituximab
_version_	1718401884207710208

NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab

Ejemplares similares